(Q34022527)

30 July 2017

title

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses (English)

1 reference

30 July 2017

1 reference

1 reference

Deborah A Marshall

2

0 references

author name string

Ilia L Ferrusi

1

1 reference

30 July 2017

Nathalie A Kulin

3

1 reference

30 July 2017

Natasha B Leighl

4

1 reference

30 July 2017

Kathryn A Phillips

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

30 July 2017

published in

Personalized Medicine

1 reference

30 July 2017

volume

6

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

193-215

1 reference

Trastuzumab: a pharmacoeconomic review of its use in early breast cancer

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

The statistical basis of meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910630

How much will Herceptin really cost? The money is already there

5 July 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.6.2.193

How much will Herceptin really cost? Balancing local and national priorities is not new.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.6.2.193

Patient demand and politics push Herceptin forward

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.6.2.193

Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.6.2.193

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.6.2.193

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.6.2.193

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

12 December 2020

Roche responds to the 'Herceptin or deception' article

1 reference

12 December 2020

Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model

1 reference

12 December 2020

Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium

1 reference

12 December 2020

Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer

1 reference

12 December 2020

PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?

1 reference

12 December 2020

Is trastuzumab a cost-effective treatment for breast cancer?

1 reference

12 December 2020

Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France

1 reference

12 December 2020

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer

1 reference

12 December 2020

Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?

1 reference

12 December 2020

PHARMAC responds on Herceptin assumptions and decisions

1 reference

12 December 2020

Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis

1 reference

12 December 2020

Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article

1 reference

12 December 2020

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

1 reference

12 December 2020

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial

1 reference

12 December 2020

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

1 reference

12 December 2020

Identifiers

DOI

10.2217/17410541.6.2.193

1 reference

30 July 2017

1 reference

30 July 2017

1 reference